<DOC>
	<DOCNO>NCT01015131</DOCNO>
	<brief_summary>This study correlate change baseline Ki-67 , immunohistochemical marker cell proliferation , change baseline tumor uptake 3'-deoxy-3 ' [ 18F ] -fluorothymidine ( 18F-FLT ) follow first cycle treatment standard care neo-adjuvant therapy participant breast cancer .</brief_summary>
	<brief_title>18F-FLT-PET Breast Cancer ( MK-0000-139 )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Alovudine</mesh_term>
	<criteria>Has newlydiagnosed stage IIB/IIIA/IIIB locally advance breast cancer Is eligible preoperative ( neoadjuvant ) chemotherapy Has contraindication magnetic resonance imaging ( MRI ) Any condition would limit ability undergo MRI PET scan Is nurse mother Has moderate endstage renal disease dialysis renal failure chronic dialysis</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>